IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials
June 24 2021 - 4:15PM
Business Wire
IQVIA™ (NYSE: IQV) today introduced Clinical Data Analytics
Suite (CDAS), a new SaaS-based clinical data analytics platform
that combines structured and unstructured data from clinical trials
into a single, standardized setting for easier access and use. This
produces a scalable repository, that helps meet regulatory
requirements, for stakeholders to investigate operational and
clinical data. It also drives faster predictive analytics using
AI/ML, enabling smarter decisions across all parts of a clinical
trial.
“The accelerating shift to decentralized trials brings an
explosion of data, including opt-in patient level data from
connected devices and patient-centric applications,” said Nagaraja
Srivatsan, chief digital officer of Research and Development
Technology Solutions, IQVIA. “Sponsors need an open platform to
ingest all trial data, including real world data, and to
standardize it into useful models. The Clinical Data Analytics
Suite supports exploration of information on demand and unlocks
previously hidden insights across systems.”
IQVIA’s CDAS transforms clinical data analytics from descriptive
reports about prior events into predictive insights that improve
trial safety for patients and quicken drug development. CDAS
automates delivery of data intelligence to clinical trial
workflows, empowering stakeholders to make smarter decisions about
study design, site selection, site risk, targeted deployment of
monitoring resources, and more. CDAS is interoperable with the rest
of IQVIA’s Orchestrated Clinical Trial solutions and existing
proprietary or third-party data archives and systems.
According to Gartner, “Clinical data analytic platforms bring
modern data and analytics approaches to clinical trial data
processes, expanding upon existing clinical data repository
solutions and data science laboratories by integrating them under a
modern logical data warehouse architecture. Clinical data analytic
platforms can improve process transparency, eliminate data siloes,
and most importantly provide a foundation for more advanced
technologies aiding new trial approaches.”
Core components of IQVIA Clinical Data Analytics Suite are
available now. Please visit http://iqvia.com/cdas for more
details.
Gartner, Hype Cycle for Life Science Research and Development,
2020, Jeff Smith, Michael Shanler, 13 August 2020
About IQVIA IQVIA (NYSE:IQV) is a leading global provider
of advanced analytics, technology solutions, and clinical research
services to the life sciences industry. IQVIA creates intelligent
connections across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 72,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors, and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210624005972/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Nick Childs, IQVIA Investor Relations
(nicholas.childs@iqvia.com) +1.973.316.3828
IQVIA (NYSE:IQV)
Historical Stock Chart
From Aug 2024 to Sep 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Sep 2023 to Sep 2024